| Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018 | 1839 | 2018 |
| Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a … AMM Eggermont, M Kicinski, CU Blank, M Mandala, GV Long, V Atkinson, ... JAMA oncology 6 (4), 519-527, 2020 | 359 | 2020 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The Lancet Oncology 22 (5), 643-654, 2021 | 325 | 2021 |
| Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi, P Wung, N Patel, ... The Lancet Respiratory Medicine 9 (5), 522-532, 2021 | 271 | 2021 |
| Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial AMM Eggermont, CU Blank, M Mandala, GV Long, VG Atkinson, S Dalle, ... Journal of clinical oncology 38 (33), 3925-3936, 2020 | 251 | 2020 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 237 | 2018 |
| Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors A Elkrief, L El Raichani, C Richard, M Messaoudene, W Belkaid, J Malo, ... Oncoimmunology 8 (4), e1568812, 2019 | 179 | 2019 |
| Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors MD Hellmann, TW Kim, CB Lee, BC Goh, WH Miller Jr, DY Oh, R Jamal, ... Annals of Oncology 30 (7), 1134-1142, 2019 | 143 | 2019 |
| Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial B Routy, JG Lenehan, WH Miller Jr, R Jamal, M Messaoudene, ... Nature medicine 29 (8), 2121-2132, 2023 | 108 | 2023 |
| Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC SJ Antonia, A Balmanoukian, J Brahmer, SHI Ou, MD Hellmann, SW Kim, ... Journal of thoracic Oncology 14 (10), 1794-1806, 2019 | 85 | 2019 |
| Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, VG Atkinson, S Dalle, ... European Journal of Cancer 116, 148-157, 2019 | 85 | 2019 |
| Spatially mapping the immune landscape of melanoma using imaging mass cytometry D Moldoveanu, LA Ramsay, M Lajoie, L Anderson-Trocme, M Lingrand, ... Science immunology 7 (70), eabi5072, 2022 | 77 | 2022 |
| Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor … A Arance, L De La Cruz-Merino, TM Petrella, R Jamal, L Ny, A Carneiro, ... Journal of Clinical Oncology 41 (1), 75-85, 2023 | 73 | 2023 |
| Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma AMM Eggermont, M Kicinski, CU Blank, M Mandala, GV Long, V Atkinson, ... NEJM evidence 1 (11), EVIDoa2200214, 2022 | 72 | 2022 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised … A Bottomley, C Coens, J Mierzynska, CU Blank, M Mandalà, GV Long, ... The lancet oncology 22 (5), 655-664, 2021 | 55 | 2021 |
| Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma H Bahig, F Aubin, J Stagg, O Gologan, O Ballivy, E Bissada, ... BMC cancer 19, 1-15, 2019 | 52 | 2019 |
| Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC) SJ Antonia, JR Brahmer, S Khleif, AS Balmanoukian, SHI Ou, M Gutierrez, ... Annals of oncology 27, vi421, 2016 | 51 | 2016 |
| Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma R Jamal, R Lapointe, E Cocolakis, P Thébault, S Kazemi, JE Friedmann, ... Journal for immunotherapy of cancer 5, 1-13, 2017 | 46 | 2017 |
| Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma OJ Kennedy, M Kicinski, S Valpione, S Gandini, S Suciu, CU Blank, ... European journal of cancer 165, 97-112, 2022 | 28 | 2022 |
| Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004. AM Arance, L de la Cruz-Merino, TM Petrella, R Jamal, L Ny, A Carneiro, ... Journal of Clinical Oncology 39 (15_suppl), 9504-9504, 2021 | 27 | 2021 |
